期刊文献+

培美曲塞治疗老年晚期非小细胞肺癌的临床疗效分析

在线阅读 下载PDF
导出
摘要 比较培美曲塞与吉西他滨分别联合卡铂对老年晚期非小细胞肺癌(NSCLC)的临床疗效及毒副反应。将86例老年晚期NSCLC患者随机分为研究组和对照组各43例,研究组采用培美曲塞联合卡铂治疗,对照组采用吉西他滨联合卡铂治疗,治疗2个周期后,比较两组的临床疗效及毒副反应。研究组客观有效率(ORR)、疾病控制率(DCR)与对照组比较,差异无统计学意义(P〉0.05);研究组WBC减少、贫血、血小板降低及胃肠道反应Ⅲ~Ⅳ级发生率均明显低于对照组(P〈0.05)。培美曲塞与吉西他滨分别联合卡铂治疗老年NSCLC取得的临床疗效相当,但培美曲塞联合卡铂的毒副反应较吉西他滨联合卡铂相对较轻,值得临床推荐使用。
作者 付英
出处 《现代诊断与治疗》 CAS 2016年第4期661-662,共2页 Modern Diagnosis and Treatment
  • 相关文献

参考文献6

二级参考文献58

  • 1Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011,61 (2):69-90.
  • 2Rollins KD, Lindly C. Pemetrexed: a muhitargetedantifolate[J]. Clin Ther, 2005, 27(9):1343-1382.
  • 3Scagliotti GV, Kortsik C, Dard GG, et al. Pemetrexed combined withoxaliplatin or carboplatin as first-line treatment in advanced- non-small cell lung cancer:amulticenter,phase IItrial[J]. Clin Can- cer Res, 2005, 11:690-696.
  • 4Hanna N, Shepherd FA, Fossela FV, et al. Random lzedphase trial of pemetrexedversus docetaxel in patients with non- small cell lung cancer previously treated with chemotherapy. J Clin Onco, 2004, 22(9):1589-1597.
  • 5Cluleanu TE, Brodowicz T, Belani CP, et al. Maintenance peme- trexedplus best supportive care(BSC)versus placebo plus BSC:A phase IIIstudy[J].JClinOncol, 2008, 26(1):426.
  • 6Scagliotti GV,Parikh P,Von PawelJ,et al. Phase III study comparing- cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemo- therapy-nave patients with advanced-stage non-small-cell lung cancer[J].JClinOncol, 2008, 26:3543-3551.
  • 7Peterson P, Park K, Fossella F, et al. Is pemetrexed more effective in- adenocarcinoma and large cell carcinoma than in squamous cell car- cinoma A retrospective analysis of a phase m trial of pemetrexedvs-docetaxel in previously treated patients with advanced- non-small-celllung cancer[J]. J Thorac Oncol, 2007, 2(4):$851.
  • 8Ohe Y, Ichinose Y, Nakagawa T, et al. Efficacy and safety of two doses ofpemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small-cell lung cancer[J]. Clin Cancer Res. 9008, 14:4206-4212.
  • 9E.A. Eisenhauer,P. Therasse,J. Bogaerts,L.H. Schwartz,D. Sargent,R. Ford,J. Dancey,S. Arbuck,S. Gwyther,M. Mooney,L. Rubinstein,L. Shankar,L. Dodd,R. Kaplan,D. Lacombe,J. Verweij.New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)[J]. European Journal of Cancer . 2008 (2)
  • 10Denis Moro-Sibilot,Alain Vergnenegre,Egbert F. Smit,Elisabeth Toy,Barbara Parente,Stephan Schmitz,Kees Kraaij,Carla Visseren-Grul,Victoria Soldatenkova,Jorge Arellano,Claudia Leteneux.Second-line therapy for NSCLC in clinical practice: baseline results of the European SELECTTION observational study[J].Current Medical Research & Opinion.2010(11)

共引文献187

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部